Stocktwits1h fa · leggi qui →
SNOW, CDNA Stocks Hit Fresh 52-Week Highs – What’s Driving Investor Optimism Today?
Snowflake and CareDx received favorable reviews from Wall Street firms, following better-than-expected second-quarter prints and bullish momentum across AI products, respectively.…
Motley Fool2g fa · leggi qui →
Why CareDx Stock Jumped Today
The diagnostics leader is accelerating the trend toward precision medicine.…
Investor's Business Daily3g fa · leggi qui →
Medical Test Name Explodes To A High After Earnings
A bank stock hits an all-time high while a medical test provider reaches a buy point of an unusual bullish chart pattern.…
MT Newswires3g fa · leggi qui →
Top Midday Gainers
Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of th…
MarketBeat3g fa · leggi qui →
CareDx Q2 Earnings Call Highlights
CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integ…
Zacks3g fa · leggi qui →
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
CareDx (CDNA) delivered earnings and revenue surprises of +68.18% and +15.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?…
Zacks11g fa · leggi qui →
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…
Simply Wall St.15g fa · leggi qui →
CareDx (CDNA) Is Up 39.4% After Medicare Clarifies Transplant Test Coverage Limits - What's Changed
CareDx, Inc. previously announced that Medicare finalized a Local Coverage Determination for molecular testing to monitor solid organ transplant rejection, affirming coverage for its AlloSure Kidney, …
Simply Wall St.16g fa · leggi qui →
CareDx (CDNA) Secures Medicare Reimbursement Clarity, Is The Upside Already Priced In?
CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination for molecular testing in solid organ transplants, confirming reimbursement for the company’s kidney, heart, and l…
Simply Wall St.16g fa · leggi qui →
CareDx (CDNA) Stock May Be Fully Valued Despite Medicare Coverage News
CareDx stock has delivered a very strong 273.8% return over the past three years. However, its current valuation checks and recent share price strength point to a stock that may now be leaning expensi…